The HIV Vaccine Trials Network (HVTN) is the largest clinical trials program devoted to the development and testing of preventive HIV vaccines worldwide. The Network’s investigators, who are leaders in HIV and vaccine research in their countries, work collectively as a driving force in the search for an effective HIV vaccine.
The HVTN is committed to coordination, information sharing and global collaboration to find an effective HIV vaccine—exemplified by the participation of senior HVTN investigators in the genesis of the Global HIV Vaccine Enterprise.
Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services (DHHS). The Network and NIAID have a close, cooperative working relationship, with shared attention to the intellectual and scientific issues.
The Network’s HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. Internationally renowned HIV vaccine and prevention researchers lead the units. The Network’s headquarters are at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The HVTN has strong relationships with inventors of vaccines and a wide variety of scientists working in the areas of HIV virology, immunology, and pathogenesis.
Please direct inquires to:
Jim Maynard, MDiv
Associate Director for Communications and Community Engagement
HIV Vaccine Trials Network